Literature DB >> 24900775

Synthesis and in Vitro Evaluation of a Peptidomimetic Inhibitor Targeting the Src Homology 2 (SH2) Domain of STAT6.

Pietro Morlacchi1, Pijus K Mandal1, John S McMurray1.   

Abstract

An improved synthesis of a phosphopeptidomimetic prodrug targeting the Src Homology 2 (SH2) domain of signal transducer and activator of transcription 6 (STAT6) is reported. In our convergent methodology, we employed a phosphotyrosine surrogate active ester harboring pivaloyloxymethyl groups, which efficiently coupled to tert-butylglycinyl proline diarylamide. Biological evaluation of 1 has not been reported. We show that it inhibits STAT6 phosphorylation in intact human bronchial epithelial cells, suggesting potential application in the treatment of asthma.

Entities:  

Keywords:  Peptidomimetic inhibitor; SH2; STAT6; prodrug

Year:  2013        PMID: 24900775      PMCID: PMC4027771          DOI: 10.1021/ml4003919

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  12 in total

1.  Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide.

Authors:  Christine T McCusker; Yufa Wang; Jichuan Shan; Margaret W Kinyanjui; Annie Villeneuve; Husheem Michael; Elizabeth D Fixman
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

Review 2.  Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma.

Authors:  Douglas A Kuperman; Robert P Schleimer
Journal:  Curr Mol Med       Date:  2008-08       Impact factor: 2.222

3.  Signal transducer and activator of transcription 6 (STAT-6) expression and function in asthmatic bronchial epithelium.

Authors:  R E Mullings; S J Wilson; S M Puddicombe; J L Lordan; F Bucchieri; R Djukanović; P H Howarth; S Harper; S T Holgate; D E Davies
Journal:  J Allergy Clin Immunol       Date:  2001-11       Impact factor: 10.793

4.  Specific inhibition of interleukin-4-dependent Stat6 activation by an intracellularly delivered peptide.

Authors:  S Stolzenberger; M Haake; A Duschl
Journal:  Eur J Biochem       Date:  2001-09

5.  Effective treatment of experimental ragweed-induced asthma with STAT-6-IP, a topically delivered cell-penetrating peptide.

Authors:  Y Wang; Y Li; J Shan; E Fixman; C McCusker
Journal:  Clin Exp Allergy       Date:  2011-09-20       Impact factor: 5.018

6.  Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3.

Authors:  Pijus K Mandal; Warren S-L Liao; John S McMurray
Journal:  Org Lett       Date:  2009-08-06       Impact factor: 6.005

7.  Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells.

Authors:  D Farquhar; S Khan; D N Srivastva; P P Saunders
Journal:  J Med Chem       Date:  1994-11-11       Impact factor: 7.446

8.  Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice.

Authors:  Yasemin Darcan-Nicolaisen; Holger Meinicke; Gabriele Fels; Olga Hegend; Annekathrin Haberland; Anja Kühl; Christoph Loddenkemper; Martin Witzenrath; Stefanie Kube; Wolfgang Henke; Eckard Hamelmann
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

Review 9.  New asthma drugs acting on gene expression.

Authors:  F-D Popescu
Journal:  J Cell Mol Med       Date:  2003 Oct-Dec       Impact factor: 5.310

10.  Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors.

Authors:  T R Burke; M S Smyth; A Otaka; M Nomizu; P P Roller; G Wolf; R Case; S E Shoelson
Journal:  Biochemistry       Date:  1994-05-31       Impact factor: 3.162

View more
  5 in total

1.  Small molecule targeting of the STAT5/6 Src homology 2 (SH2) domains to inhibit allergic airway disease.

Authors:  J Morgan Knight; Pijus Mandal; Pietro Morlacchi; Garbo Mak; Evan Li; Matthew Madison; Cameron Landers; Brandon Saxton; Ed Felix; Brian Gilbert; Joel Sederstrom; Atul Varadhachary; Melissa M Singh; Dev Chatterjee; David B Corry; John S McMurray
Journal:  J Biol Chem       Date:  2018-05-08       Impact factor: 5.157

Review 2.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

3.  Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity.

Authors:  Pijus K Mandal; Pietro Morlacchi; J Morgan Knight; Todd M Link; Gilbert R Lee; Roza Nurieva; Divyendu Singh; Ankur Dhanik; Lydia Kavraki; David B Corry; John E Ladbury; John S McMurray
Journal:  J Med Chem       Date:  2015-11-09       Impact factor: 7.446

4.  Rational development of Stafib-2: a selective, nanomolar inhibitor of the transcription factor STAT5b.

Authors:  Nagarajan Elumalai; Angela Berg; Stefan Rubner; Linda Blechschmidt; Chen Song; Kalaiselvi Natarajan; Jörg Matysik; Thorsten Berg
Journal:  Sci Rep       Date:  2017-04-11       Impact factor: 4.379

Review 5.  Targeting cell signaling in allergic asthma.

Authors:  Seyyed Shamsadin Athari
Journal:  Signal Transduct Target Ther       Date:  2019-10-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.